文献速递淋巴瘤

以抗体药物偶联物卡米丹鲁单抗替西林单药或联合靶向药物治疗CD25阳性淋巴瘤细胞

Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.
PubMed 文献 · Br J Haematol · 2024-07-30

卡米丹鲁单抗替西林(ADCT-301)是靶向CD25的抗体药物偶联物,在57种淋巴瘤细胞系中评估单药活性,并在T细胞淋巴瘤衍生细胞系中评估与选定药物的联合。单药在T细胞淋巴瘤中体外细胞毒活性强于B细胞淋巴瘤,且与CD25细胞表面和RNA表达相关;与依维莫司、库潘尼西、维奈克拉、伏立诺他和普拉曲沙联合最为活跃。

要点

  • 卡米丹鲁单抗替西林单药在T细胞淋巴瘤细胞系中体外细胞毒活性强于B细胞淋巴瘤。
  • 体外活性与CD25细胞表面及RNA表达水平相关。
  • 在四个T细胞淋巴瘤模型中,最活跃的联合伙伴为依维莫司、库潘尼西、维奈克拉、伏立诺他和普拉曲沙。

核心结论

  • 卡米丹鲁单抗替西林单药具有强抗淋巴瘤活性,与靶向药物在体外协同,为未来临床研究提供潜在联合伙伴。

研究设计与样本

  • 在57种淋巴瘤细胞系中评估卡米丹鲁单抗替西林单药临床前活性,并在T细胞淋巴瘤衍生细胞系中评估与选定药物的联合。
  • 细胞暴露于递增浓度的ADC或SG3199 96小时,随后进行MTT增殖实验。
  • 在细胞表面和RNA水平检测CD25表达,并使用PDX衍生细胞系进行验证研究。

主要发现

  • 卡米丹鲁单抗替西林单药在T细胞淋巴瘤中的体外细胞毒活性强于B细胞淋巴瘤。
  • 体外活性与CD25细胞表面和RNA表达相关。
  • 在四个T细胞淋巴瘤模型中评估含卡米丹鲁单抗替西林的联合方案,最活跃的伙伴为依维莫司、库潘尼西、维奈克拉、伏立诺他和普拉曲沙,其后为硼替佐米、罗米地辛、苯达莫司汀和5-阿扎胞苷。

关键数值与推荐

  • 单药在57种淋巴瘤细胞系中评估,联合在T细胞淋巴瘤衍生细胞系中评估。
  • 细胞暴露于递增浓度ADC或SG3199 96小时。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Camidanlumab tesirine (ADCT-301) is a CD25-specific antibody-drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross-linking pyrrolobenzodiazepine dimer. The ADC has shown early clinical antitumour activity in various cancers, including B- and T-cell lymphomas. We assessed its preclinical activity as a single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphoma-derived cell lines. Cells were exposed to increasing concentrations of the ADC or SG3199 for 96 h, followed by an MTT proliferation assay. CD25 expression was measured at cell surface and RNA levels. Experiments with PDX-derived cell lines were used for validation studies. Camidanlumab tesirine presented more potent single agent in vitro cytotoxic activity in T- than B-cell lymphomas. In vitro activity was correlated with CD25 cell surface and RNA expression. In vitro activity was correlated with CD25 cell surface and RNA expression. When camidanlumab tesirine-containing combinations were evaluated in four T-cell lymphoma models, the most active partners were everolimus, copanlisib, venetoclax, vorinostat, and pralatrexate, followed by bortezomib, romidepsin, bendamustine, and 5-azacytidine. The strong camidanlumab tesirine single-agent anti-lymphoma activity and the in vitro synergisms with targeted agents identify potential combination partners for future clinical studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Spriano F, Tarantelli C, Cascione L, et al. Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. Br J Haematol. 2024. PMID: 39080847. doi:10.1111/bjh.19658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。